June CVP Update

In this Issue:

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021 | MMWR

On May 12, 2021, after a systematic review of all available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years for the prevention of COVID-19. The Pfizer-BioNTech COVID-19 vaccine is the first COVID-19 vaccine approved for use in adolescents and has high efficacy against symptomatic COVID-19. Vaccination will be important to protect adolescents against symptomatic COVID-19 disease and to reduce community transmission of SARS-CoV-2.

Updated Interim Clinical Considerations for use of COVID-19 Vaccines

COVID-19 vaccines and other vaccines **may now be administered without regard to timing**. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines. **If multiple vaccines are administered at a single visit, administer each injection in a different injection site.** For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection.

Enrollment for CVP Providers to Administer COVID-19 Vaccines

Please review the process on our website if you wish to enroll in the CoVP. Even if you have access to the user interface (UI) or onboarded your EHR for electronic reporting to CT WiZ, you will need to complete all 6 steps before you can place your order request for COVID-19 vaccines.

Patient Education Materials Ordering Update:

If you need to order educational materials for your patients oradditional birthing hospital materials, DPH has posted the new ordering forms on our website under "Patient Education". Additionally, we have a new process for submitting your order:

- Download and complete the appropriate order form.
- Go to our helpdesk website to submit a ticket.
- Select "Immunizations Program", then "Immunization Educational Materials Orders", and then either "Educational Materials Order" or "Birthing Hospital Materials Order".
- Click the "Here" button to be prompted further to submit a ticket.
- Enter your information and upload your completed order form.

Follow us on Social Media!

Facebook: @CTPublicHealth

Twitter: @CTDPH

Contact Us: **860-509-7929**

or click here

For a current list of IAP Contacts, Map and Social Media visit Immunization Action Plan (IAP)

CT COVID-19 Webpages:

- DPH Mobile Van Clinics
- Complete this form to request a van
- Connecticut's Vaccine Locator Portal
- CT DPH COVID-19 Vaccination FAQs
- Latest COVID-19 Guidance

New CVP Vaccines

Vaxelis™ Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine

New DTaP/IPV/HiB/Hep B Vaccine

The Food & Drug Administration (FDA) has approved a new combination vaccine that protects against 6 diseases. Vaxelis (CPT Code 90697) is indicated for active immunization for the prevention of diphtheria, tetanus, pertussis, polio, *Haemophilus influenza* type b, and hepatitis b disease. Vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

The 3-dose schedule for Vaxelis consists of a 0.5 mL intramuscular injection at 2, 4, and 6 months of age. The vaccine is stored in the refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Children who have received a 3-dose series of Vaxelis should complete the primary and pertussis vaccination series with Pentacel®, Quadracel® or Daptacel® according to the respective prescribing information in the approved package inserts. Vaxelis may be used to complete the first 3 doses of the 5-dose DTaP series in infants and children who have received 1 or 2 doses of Pentacel® or Daptacel® and are also scheduled to receive the other antigens in Vaxelis.

A 3-dose series of Vaxelis may be administered to infants born to hepatitis B surface antigen (HBsAg)-negative mothers, and who have received a dose of any hepatitis B vaccine prior to or at 1 month of age. Vaxelis may be used to complete the hepatitis B vaccination series following 1 or 2 doses of other hepatitis B vaccines, in infants and children born to HBsAg-negative mothers and who are also scheduled to receive the other antigens in Vaxelis.

Vaxelis may be administered to infants and children who have received 1 or 2 doses of inactivated polio vaccine and are also scheduled to receive the other antigens in Vaxelis. Vaxelis may be administered to infants and children who have received 1 or 2 doses of *Haemophilus influenza* type b conjugate vaccine and are also scheduled to receive the other antigens in Vaxelis. The full prescribing information for Vaxelis can be found on their website.

Beginning July 1, 2021 the CVP will begin supplying Vaxelis for routine vaccination of all children 2 months through 59 months of age. If you are planning to order and administer Vaxelis, please be sure to utilize your existing inventory of vaccines before making the switch to avoid any potential wastage.

MenQuadfi™ Meningococcal (Groups A, C, Y, W) Conjugate Vaccine

New Meningococcal Vaccine

The FDA has also approved a new vaccine for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, & W. MenQuadfi (CPT Code 90619) is approved for use in individuals 2 years of age and older. The schedule for MenQuadfi is similar to that of Menactra® with a primary dose administered at the 11-12 year adolescent visit and a subsequent booster dose administered to those individuals 15 years of age and older with at least 4 years elapsed since their previous dose of meningococcal conjugate vaccine.

MenQuadfi consists of a 0.5 mL intramuscular injection. The vaccine is stored in the refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). MenQuadfi may be administered to children and adolescents who have received a previous dose of Menactra®.

Beginning July 1, 2021 the CVP will begin supplying MenQuadfi for routine vaccination of all adolescents 11 through 18 years of age as well as for any high-risk patients in need of meningococcal conjugate vaccine 2 through 10 years of age. If you are planning to order and administer MenQuadfi, please be sure to utilize your existing inventory of Menactra® before making the switch to avoid any potential wastage. The CVP will continue to offer Menactra® as long as the vaccine remains available on the federal CDC contract which is expected to be continue through April 2022.

- Reconciliations for CVP must be done monthly.
  - If your clinic is live on CT WiZ, refer to our training page for step-by-step directions on the reconciliation process.
    - Direct Data Entry Reconciliation training slides
    - HL7 Reconciliation training slides
- CDC is now limiting the number of characters we can use in clinic names, so you may notice that your clinic name has been shortened in CT WiZ.